• Successfully implemented 2 clinical trials and passed 11 patents granted in US and international. • Developed platform technology (5 drug candidates), 1 from bench to bedside• Streamlining expansion of three research programs in two significant medical departments at MD Anderson.• Lead representative during drug testing and diligence phases.• Co-authored publications on Phase I and Phase II program studies. • Managed and identified goals, timelines and deliverables for onboarding research partners and Biology and Pharmacology groups.• Prepared meetings, visual presentations, and documentation for Food and Drug Administration (FDA) during pre-IND meeting phases and clinical trials (IB,SIV, annual reporting).• Drafted Patient Informed Consent (PIC) documents, specifications and continuing stability of clinical drug product, study manuals, pharmacy manuals, and case report forms.

• Received funding from the Department of Defense to develop a targeted prostate cancer therapy for early metastases using lytic peptide conjugates with $334,744 (2003-2007) budget. Information was presented at the “Innovative Minds in Prostate Cancer Today” (IMPACT) conference in Atlanta in 2007.• Received funding from Esperance Pharmaceuticals: Pre-clinical development of lytic peptide conjugates forcancer treatment. October 17, 2006 – October 15, 2007, $ 750,000, PI: Carola Leuschner• Grant reviewer in study sections Nanotechnology for Alliance for Nano Health Research Program (NIH), Molecular Imaging and Nano Medicine (SG Komen Foundation) and Human Health and Development at the Kentucky Science and Engineering Foundation• Co-Investigator in a NIH funded study in the Rapid Access to Intervention Development (RAID) program for targeted destruction of prostate, ovarian and testicular cancers and their metastases by a lytic peptide conjugate (2005-2007).• Published study data in 12 peer reviewed journals, 19 peer reviewed abstracts, 8 invited presentations, 2book chapters that led to 4 patent applications.